The publication of this video was sponsored by LEO Pharma.
Prescribing information for Adtralza▼ (tralokinumab) can be found here.
Explore the impact of atopic dermatitis on visible areas like the head and neck, affecting approximately 70% of patients with moderate to severe cases. This condition significantly impacts quality of life, potentially leading to increased anxiety and depression. In this video, we examine tralokinumab data specifically for the head and neck region.
The video is presented by Melinda Gooderham and April Armstrong.
Speakers:
Melinda Gooderham1-3
April Armstrong4
1. SkiN Centre for Dermatology, Peterborough, Canada
2. Probity Medical Research, Peterborough, Canada
3. Queen’s University, Peterborough, Canada
4. Division of Dermatology, University of California, Los Angeles, USA
| Reporting of Suspected Adverse Reactions Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google Play or Apple App Store. Adverse events should also be reported to Drug Safety at LEO Pharma by calling +44 (0)1844 347333 or e-mail: [email protected] |
